Physician profile
Elyse Marie Schultz
NPI 1285139964
$3,097.04
in general payments reported to CMS, 2019-2025
26 companies · $755 in 2025
The $755 reported for 2025 was more than what 88% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $23.25 · 2021: $42.42 · 2022: $394 · 2023: $933 · 2024: $949 · 2025: $755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,637.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,637.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $355.18 | 2022-2025 | Nexplanon, Nuvaring, Jada System |
| Mayne Pharma Commercial LLC | $286.83 | 2022-2025 | |
| Exeltis, USA INC. | $263.61 | 2022-2025 | Slynd |
| Abbvie INC. | $217.19 | 2022-2025 | Lo Loestrin Fe, Liletta, Orilissa |
| Agile Therapeutics, INC. | $191.55 | 2022-2024 | Twirla |
| Shield Therapeutics INC | $188.79 | 2023-2024 | Accrufer |
| Pfizer INC. | $186.50 | 2024-2025 | |
| Coopersurgical, INC. | $186.31 | 2022-2024 | Paragard T 380a, Paragard T 380a |
| Hologic Sales and Service, LLC | $136.71 | 2022-2025 | Aptima, Thinprep 2000 Processor |
| Astellas Pharma US INC | $128.69 | 2024-2025 | Veozah |
| Myriad Women'S Health, INC. | $122.25 | 2023 | Myrisk |
| Exact Sciences Corporation | $108.20 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $88.43 | 2022-2024 | Gardasil 9, Gardasil |
| Biogen, INC. | $77.65 | 2025 | Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $74.54 | 2023-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $67.50 | 2023 | Balcoltra |
| Medical Device Business Services, INC. | $65.67 | 2020-2021 | |
| Novo Nordisk INC | $64.76 | 2023-2025 | Wegovy |
| Becton, Dickinson and Company | $58.95 | 2022-2023 | Bd Onclarity |
| Amgen INC. | $57.60 | 2024 | Prolia, Evenity |
| Millicent US INC | $49.97 | 2024-2025 | Femlyv, Femring, Intrarosa |
| Dexcom, INC. | $34.46 | 2025 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $26.93 | 2023 | Myfembree |
| Seqirus USA INC | $22.11 | 2024 | Flucelvax, Fluad |
| Channel Medsystems, INC. | $19.70 | 2022 | |
| Monaghan Medical Corporation | $16.96 | 2023 | Aerobika |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elyse Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.